Management of Stage III Oral Cavity Squamous Cell Carcinoma in Light of the New Staging System: a Critical Review

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMATOS, Leandro Luongo
dc.contributor.authorGUIMARAES, Yasmin Laryssa Moura
dc.contributor.authorLEITE, Ana Kober
dc.contributor.authorCERNEA, Claudio Roberto
dc.date.accessioned2023-02-23T14:47:31Z
dc.date.available2023-02-23T14:47:31Z
dc.date.issued2023
dc.description.abstractPurpose of Review Oral squamous cell carcinoma (OSCC) patients have a poor prognosis, especially in advanced stages. AJCC/UICC staging system 8th edition (TNM8) included depth of invasion (DOI) as part of T staging and stage III has become a heterogeneous group of lesions, composed of patients with larger DOI and/or width. Additionally, stage III includes N1, regardless of the primary tumor width or DOI. The real prognostic value of each of these characteristics and the need for adjuvant treatment for stage III patients is not well established. Recent Findings TNM8 stratified OSCC into prognostic groups based on overall survival. Extranodal extension, positive or close margins, pT3 or pT4 tumors, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion are the main adverse features for OSCC, and adjuvant treatment is largely recommended for these patients. Summary Stage III patients should be addressed with caution. So far, there is no significant evidence for recommending or excluding adjuvant treatment for stage III OSCC without adverse features. The authors largely recommend adjuvant radiotherapy for these cases, especially because pT3 without adverse features is rare. Further studies on this topic are necessary.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationCURRENT ONCOLOGY REPORTS, v.25, n.2, p.107-113, 2023
dc.identifier.doi10.1007/s11912-022-01353-6
dc.identifier.eissn1534-6269
dc.identifier.issn1523-3790
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/51371
dc.language.isoeng
dc.publisherSPRINGEReng
dc.relation.ispartofCurrent Oncology Reports
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright SPRINGEReng
dc.subjectOral neoplasmseng
dc.subjectNeoplasm stagingeng
dc.subjectLymph node metastasiseng
dc.subjectPrognosiseng
dc.subject.otherrisk-factorseng
dc.subject.otherbuccal mucosaeng
dc.subject.otherneck-cancereng
dc.subject.otherlong-termeng
dc.subject.otherheadeng
dc.subject.othersurvivaleng
dc.subject.otherradiotherapyeng
dc.subject.otherchemotherapyeng
dc.subject.otherpredictioneng
dc.subject.othernomogramseng
dc.subject.wosOncologyeng
dc.titleManagement of Stage III Oral Cavity Squamous Cell Carcinoma in Light of the New Staging System: a Critical Revieweng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcLEANDRO LUONGO DE MATOS
hcfmusp.contributor.author-fmusphcYASMIN LARYSSA MOURA GUIMARAES
hcfmusp.contributor.author-fmusphcANA KOBER NOGUEIRA LEITE
hcfmusp.contributor.author-fmusphcCLAUDIO ROBERTO CERNEA
hcfmusp.description.beginpage107
hcfmusp.description.endpage113
hcfmusp.description.issue2
hcfmusp.description.volume25
hcfmusp.origemWOS
hcfmusp.origem.pubmed36585962
hcfmusp.origem.scopus2-s2.0-85145185430
hcfmusp.origem.wosWOS:000906304000003
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUNITED STATESeng
hcfmusp.relation.referenceAires FT, 2017, ORL J OTO-RHINO-LARY, V79, P347, DOI 10.1159/000485627eng
hcfmusp.relation.referenceAlmangush A, 2020, HEAD NECK-J SCI SPEC, V42, P3002, DOI 10.1002/hed.26344eng
hcfmusp.relation.referenceAmin M.B., 2017, AJCC CANC STAGING MA, V8th ed.eng
hcfmusp.relation.referenceBernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641eng
hcfmusp.relation.referenceBest CAE, 2019, J OTOLARYNGOL-HEAD N, V48, DOI 10.1186/s40463-019-0396-xeng
hcfmusp.relation.referenceBobdey S, 2018, ORAL ONCOL, V81, P10, DOI 10.1016/j.oraloncology.2018.04.002eng
hcfmusp.relation.referenceBobdey S, 2016, HEAD NECK-J SCI SPEC, V38, P1826, DOI 10.1002/hed.24507eng
hcfmusp.relation.referenceCaldeira PC, 2020, ORAL DIS, V26, P1357, DOI 10.1111/odi.13194eng
hcfmusp.relation.referenceChang BY, 2018, J CANCER, V9, P2107, DOI 10.7150/jca.24530eng
hcfmusp.relation.referenceChen WC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003770eng
hcfmusp.relation.referenceCooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646eng
hcfmusp.relation.referenced'Alessandro AF, 2015, BRAZ J OTORHINOLAR, V81, P248, DOI 10.1016/j.bjorl.2015.03.004eng
hcfmusp.relation.referenceFerreli F, 2021, ORAL ONCOL, V122, DOI 10.1016/j.oraloncology.2021.105540eng
hcfmusp.relation.referenceGokavarapu S, 2015, OR SURG OR MED OR PA, V120, DOI 10.1016/j.oooo.2015.08.002eng
hcfmusp.relation.referenceHamman J, 2022, LARYNGOSCOPE, V132, P307, DOI 10.1002/lary.29690eng
hcfmusp.relation.referenceHasmat S, 2019, HEAD NECK-J SCI SPEC, V41, P3992, DOI 10.1002/hed.25940eng
hcfmusp.relation.referenceHuang SH, 2020, ORAL ONCOL, V102, DOI 10.1016/j.oraloncology.2019.104563eng
hcfmusp.relation.referenceHuang SJ, 2021, OR SURG OR MED OR PA, V131, P319, DOI 10.1016/j.oooo.2020.10.026eng
hcfmusp.relation.referenceHuang TH, 2019, ORAL ONCOL, V89, P133, DOI 10.1016/j.oraloncology.2018.12.032eng
hcfmusp.relation.referenceLee Oh Hyeong, 2022, J Oral Maxillofac Surg, V80, P553, DOI 10.1016/j.joms.2021.11.003eng
hcfmusp.relation.referenceLeite AKN, 2014, ACTA OTORHINOLARYNGO, V34, P389eng
hcfmusp.relation.referenceLi Y, 2017, CANCER MED-US, V6, P1002, DOI 10.1002/cam4.1021eng
hcfmusp.relation.referenceMair M, 2018, HEAD NECK-J SCI SPEC, V40, P1667, DOI 10.1002/hed.25161eng
hcfmusp.relation.referenceMatos LL, 2017, ORAL ONCOL, V71, P47, DOI 10.1016/j.oraloncology.2017.05.020eng
hcfmusp.relation.referenceMatsuura D, 2018, LARYNGOSCOPE, V128, P1113, DOI 10.1002/lary.26935eng
hcfmusp.relation.referenceMembreno PV, 2021, HEAD NECK-J SCI SPEC, V43, P3165, DOI 10.1002/hed.26779eng
hcfmusp.relation.referenceMermod M, 2016, ORAL ONCOL, V62, P60, DOI 10.1016/j.oraloncology.2016.10.003eng
hcfmusp.relation.referenceMishra RC, 1996, EUR J SURG ONCOL, V22, P502, DOI 10.1016/S0748-7983(96)92969-8eng
hcfmusp.relation.referenceMontero PH, 2015, SURG ONCOL CLIN N AM, V24, P491, DOI 10.1016/j.soc.2015.03.006eng
hcfmusp.relation.referenceMontero PH, 2014, CANCER-AM CANCER SOC, V120, P214, DOI 10.1002/cncr.28407eng
hcfmusp.relation.referenceNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2022, HEAD NECK CANCeng
hcfmusp.relation.referenceNie ZL, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08106-xeng
hcfmusp.relation.referencePETERS LJ, 1993, INT J RADIAT ONCOL, V26, P3, DOI 10.1016/0360-3016(93)90167-Teng
hcfmusp.relation.referencePinto FR, 2014, EUR ARCH OTO-RHINO-L, V271, P1747, DOI 10.1007/s00405-013-2704-9eng
hcfmusp.relation.referencePinto FR, 2011, REV ASSOC MED BRAS, V57, P171, DOI 10.1590/S0104-42302011000200014eng
hcfmusp.relation.referenceRusso D, 2021, CANCERS, V13, DOI 10.3390/cancers13225755eng
hcfmusp.relation.referenceSalama JK, 2011, ORAL ONCOL, V47, P554, DOI 10.1016/j.oraloncology.2011.05.002eng
hcfmusp.relation.referenceShabtay NW, 2020, OR SURG OR MED OR PA, V130, P363, DOI 10.1016/j.oooo.2020.04.810eng
hcfmusp.relation.referenceShim Su Jung, 2010, Radiat Oncol, V5, P43, DOI 10.1186/1748-717X-5-43eng
hcfmusp.relation.referenceShrime MG, 2010, ARCH OTOLARYNGOL, V136, P225, DOI 10.1001/archoto.2010.22eng
hcfmusp.relation.referenceSiegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]eng
hcfmusp.relation.referenceSridharan S, 2019, CANCER-AM CANCER SOC, V125, P3198, DOI 10.1002/cncr.32199eng
hcfmusp.relation.referenceSun W, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016206eng
hcfmusp.relation.referenceTandon S, 2022, LARYNGOSCOPE, V132, P1594, DOI 10.1002/lary.29990eng
hcfmusp.relation.referenceTorrecillas V, 2018, ORAL ONCOL, V85, P1, DOI 10.1016/j.oraloncology.2018.07.019eng
hcfmusp.relation.referenceTsai TY, 2022, LARYNGOSCOPE, V132, P88, DOI 10.1002/lary.29674eng
hcfmusp.relation.referenceTu IWH, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.836803eng
hcfmusp.relation.referenceWarshavsky A, 2019, JAMA OTOLARYNGOL, V145, P542, DOI 10.1001/jamaoto.2019.0784eng
hcfmusp.relation.referenceZhou JY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.652553eng
hcfmusp.relation.referenceZhu J, 2019, ACTA OTO-LARYNGOL, V139, P1038, DOI 10.1080/00016489.2019.1655167eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication6252f1ef-3813-40c2-8c62-fd8fe025610c
relation.isAuthorOfPublication3ad70ae8-85a6-4f6e-954b-3e6709cc2909
relation.isAuthorOfPublicationf5ee678c-01fd-4115-8ad5-5e334105d6bb
relation.isAuthorOfPublicationbd415fcf-df76-47ac-ac07-13bbd073c2ae
relation.isAuthorOfPublication.latestForDiscovery6252f1ef-3813-40c2-8c62-fd8fe025610c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_MATOS_Management_of_Stage_III_Oral_Cavity_Squamous_Cell_2023.PDF
Tamanho:
729.76 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/28
Artigos e Materiais de Revistas Científicas - ODS/03